

Srinivas Vourganti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4500256/publications.pdf>

Version: 2024-02-01

17
papers

96
citations

1684188

5
h-index

1372567

10
g-index

18
all docs

18
docs citations

18
times ranked

160
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis. BJU International, 2022, 130, 54-61.	2.5	6
2	Pro: Magnetic Resonance Imaging Targeting Leads to Overtreatment of Prostate Cancer. Journal of Urology, 2022, 208, 246-247.	0.4	1
3	Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer. JAMA Oncology, 2022, 8, 1128.	7.1	26
4	Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion) Tj ETQq0 0 0 rgBT /Overlock 10	2.2	6
5	Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. European Urology, 2021, 80, 386.	1.9	0
6	Assessing the diagnostic performance of systematic freehand precisionpoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 4.e9-4.e17.	1.6	0
7	A Case Series of Delayed Proximal Ureteral Strictures After Nephron-Sparing Treatment of Renal Masses. Journal of Endourology Case Reports, 2020, 6, 544-547.	0.3	0
8	Urology Residentsâ€™ Experience With Simulation: Initial Evaluation of MRI/US Fusion Biopsy Workshop. Urology, 2019, 134, 51-55.	1.0	4
9	When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion of Prostate Cancer. Journal of Urology, 2019, 201, 943-949.	0.4	5
10	Editorial Comment. Journal of Urology, 2019, 202, 935-935.	0.4	0
11	Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 341.e1-341.e7.	1.6	23
12	MR/US Fusion Technology: What Makes It Tick?. Current Urology Reports, 2017, 18, 20.	2.2	5
13	End-stage renal disease secondary to renal malignancy: Epidemiologic trends and survival outcomes. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 529.e1-529.e7.	1.6	7
14	Optimizing waiting duration for renal transplants in the setting of renal malignancy: is 2â€™years too long to wait?. Nephrology Dialysis Transplantation, 2017, 32, 1767-1773.	0.7	11
15	Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning. Current Urology Reports, 2017, 18, 93.	2.2	2
16	Re: Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 2016 (Epub ahead of print). International Urology and Nephrology, 2017, 49, 267-268.	1.4	0
17	A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT).. Journal of Clinical Oncology, 2017, 35, TPS5097-TPS5097.	1.6	0